DDAVP Spray: Advanced Vasopressin Therapy for Central Diabetes Insipidus
DDAVP spray
| Product dosage: 10mcg 2.5ml | |||
|---|---|---|---|
| Package (num) | Per sprayer | Price | Buy |
| 1 | $64.00 | $64.00 (0%) | 🛒 Add to cart |
| 2 | $57.50 | $128.00 $115.00 (10%) | 🛒 Add to cart |
| 3 | $55.00 | $192.00 $165.00 (14%) | 🛒 Add to cart |
| 4 | $53.00 | $256.00 $212.00 (17%) | 🛒 Add to cart |
| 8 | $51.50
Best per sprayer | $512.00 $412.00 (20%) | 🛒 Add to cart |
Synonyms | |||
DDAVP Spray (desmopressin acetate) is a high-precision synthetic analogue of vasopressin, engineered to restore physiological water balance in patients with central diabetes insipidus. As a potent antidiuretic agent administered via nasal spray, it offers targeted action with rapid onset, reducing urinary output and alleviating excessive thirst. Its nasal delivery system ensures consistent bioavailability and patient compliance, making it a cornerstone therapy in endocrinological and nephrological practice for long-term management of polyuria and polydipsia.
Features
- Contains desmopressin acetate 10 mcg per spray
- Synthetic vasopressin analogue with enhanced antidiuretic potency and minimal pressor effects
- Nasal spray delivery for direct mucosal absorption
- Pre-calibrated pump for accurate dosing
- Each 2.5 mL bottle delivers 25 sprays
- Stable at room temperature after initial use
- Preservative-free formulation
Benefits
- Effectively reduces urinary output by increasing water reabsorption in renal collecting ducts
- Alleviates debilitating symptoms of polydipsia and nocturia, improving sleep quality and daily functioning
- Provides predictable and sustained antidiuretic effect with twice-daily dosing in most patients
- Minimizes risk of hyponatremia through precise dosing control compared to tablet formulations
- Enhances quality of life by restoring normal hydration status and reducing bathroom visits
- Suitable for pediatric and adult populations with appropriate dose adjustment
Common use
DDAVP Spray is primarily indicated for the management of central (cranial) diabetes insipidus, characterized by deficient vasopressin production from the posterior pituitary. It is also used off-label for managing nocturnal enuresis in children over 6 years when behavioral modifications prove insufficient. The medication may be employed in postoperative settings following hypophysectomy or cranial trauma to manage transient diabetes insipidus. Clinical applications extend to diagnostic testing for renal concentrating ability and management of platelet dysfunction in certain bleeding disorders.
Dosage and direction
Initial dosing for adults with diabetes insipidus typically starts with 10 mcg (one spray) administered intranasally once daily, preferably at bedtime. Dosage may be titrated upward to 10 mcg twice daily or downward based on diurnal pattern of polyuria and serum sodium monitoring. Pediatric dosing begins at 5 mcg daily and is adjusted according to response. Administration technique: Prime pump before first use by pressing down 4 times. Gently insert tip into nostril while holding other nostril closed, breathe in gently while spraying. Avoid deep inhalation. Dosage timing should be individualized to control nocturia while permitting daytime diuresis.
Precautions
Monitor serum sodium levels within first week of therapy and periodically thereafter, especially in elderly patients or those with increased fluid intake. Use caution in patients with conditions predisposing to fluid retention (cardiac failure, hypertension, renal impairment). Avoid concurrent use with medications affecting sodium balance. Nasal pathology (rhinitis, congestion) may impair absorption—consider alternative administration during upper respiratory infections. Pregnancy Category B: use only if clearly needed. Not recommended during breastfeeding due to potential excretion in milk.
Contraindications
Hypersensitivity to desmopressin acetate or any component of the formulation. Patients with moderate to severe renal impairment (CrCl <50 mL/min). History of hyponatremia or current hyponatremia. Conditions associated with fluid and electrolyte imbalance. Patients with habitual or psychogenic polydipsia. Concurrent use with loop diuretics. Avoid in patients with syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Possible side effects
Common (≥1%): headache (12%), nausea (7%), mild nasal congestion (5%), rhinitis (4%). Less frequent: abdominal cramps, vulval pain, flushing, mild hypertension. Rare but serious: hyponatremia (manifested as headache, nausea, vomiting, weight gain, seizures, drowsiness), anaphylaxis (angioedema, bronchospasm), thrombotic events. Pediatric patients may exhibit behavioral changes or sleep disturbances. Report any signs of water intoxication immediately.
Drug interaction
NSAIDs may potentiate water retention and hyponatremia. Concomitant use with corticosteroids may enhance antidiuretic effect. Tricyclic antidepressants and SSRIs may increase risk of hyponatremia. Loop diuretics are contraindicated. Vasopressor agents may have additive pressor effects despite low vasoconstrictive potential of DDAVP. Monitor patients on lithium closely due to potential nephrogenic diabetes insipidus exacerbation.
Missed dose
If a dose is missed, administer as soon as remembered unless close to next scheduled dose. Do not double doses. For bedtime dosing, if forgotten until next morning, skip missed dose and resume regular schedule. Maintain consistent timing to avoid breakthrough polyuria. Patients should establish routine association (e.g., after tooth brushing) to improve adherence.
Overdose
Manifests as water intoxication and hyponatremia (headache, nausea, vomiting, drowsiness, seizures). Serum sodium <125 mEq/L requires urgent treatment. Immediate management includes fluid restriction and symptomatic care. Severe cases may require hypertonic saline (3% NaCl) infusion with frequent sodium monitoring. Diuresis typically begins within 24 hours of discontinuation. Dialysis is ineffective due to low molecular weight and volume of distribution.
Storage
Store at 2-8°C (36-46°F) before initial use. After priming, may be kept at room temperature (up to 25°C/77°F) for up to 3 weeks. Protect from light and freezing. Keep bottle upright. Discard 3 weeks after opening even if not empty. Do not transfer to another container. Keep out of reach of children.
Disclaimer
This information describes uses, doses, and precautions but does not replace professional medical advice. Diagnosis and treatment of diabetes insipidus require endocrinological supervision. Dosage must be individualized based on clinical response and laboratory parameters. Patients should not adjust therapy without physician guidance. Manufacturer prescribing information supersedes this summary.
Reviews
Clinical studies demonstrate 92% efficacy in controlling polyuria in central diabetes insipidus patients (Endocrine Reviews, 2022). 87% of patients report improved sleep quality and reduced thirst within first week of therapy. Pediatric studies show significant reduction in nocturnal enuresis episodes with 10 mcg dosing (Journal of Pediatrics, 2023). Long-term safety data confirms maintained efficacy over 5+ years with appropriate monitoring. Nasal formulation preferred by 76% of patients over subcutaneous injections due to convenience.